Research progress of quercetin inhibiting ACE2 in the treatment of myocardial injury caused by SARS-CoV-2

At the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory SARS coronavirus 2 (SARS-CoV-2) spread rapidly around the world. Due to the rich content of angiotensin converting enzyme 2(ACE2) on the mucosal surface of human respiratory tract, and the spike protein (S protein) on the surface of SARS-COV-2 has the function of inducing receptor recognition and binding, Receptor binding domains can specifically bind peptidase domains of ACE2. Thus, ACE2 acts as a host pathway for SARS-COV-2 infection and plays a crucial role in sarS-COV-2 infection. At the same time, the myocardial tissue ACE2 content is abundant, therefore, the myocardial tissue of patients with COVID-19 combined with myocardial injury shows abnormal expression of ACE2.The six major prescriptions of traditional Chinese medicine have remarkable effects in the prevention and treatment of COVID-19. Among them, quercetin, a monomer component of traditional Chinese medicine, has attracted more attention, and the prevention and treatment mechanism may be closely related to the inhibition of ACE2 by quercetin. Up to date, there have been few reports on drug therapy for myocardial injury caused by SARS-CoV-2.. Therefore, this paper aims to explore whether quercetin can improve myocardial injury caused by COVID-19 by inhibiting the high expression of ACE2 in myocardial tissue through literature summary and bioinformatics prediction, thereby reducing Vascular complications and cardiac mortality in patients with COVID-19.